You just read:

Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema

News provided by

Shire plc

Feb 28, 2011, 06:59 ET